ES2523903B1 - Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática - Google Patents

Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática Download PDF

Info

Publication number
ES2523903B1
ES2523903B1 ES201330636A ES201330636A ES2523903B1 ES 2523903 B1 ES2523903 B1 ES 2523903B1 ES 201330636 A ES201330636 A ES 201330636A ES 201330636 A ES201330636 A ES 201330636A ES 2523903 B1 ES2523903 B1 ES 2523903B1
Authority
ES
Spain
Prior art keywords
liver fibrosis
useful data
differential diagnosis
obtaining useful
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES201330636A
Other languages
English (en)
Other versions
ES2523903A1 (es
Inventor
Ana Isabel ROJAS GONZÁLEZ
David CANO GONZÁLEZ
Irene DELGADO SAINZ
Bernat SORIA ESCOMS
Francisco MARTÍN BERMÚDEZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacion Publica Andaluza Para La Gestion de la Investigacion En Salud De Sevilla
Universidad Pablo de Olavide
Fundacion Publica Andaluza Progreso y Salud
Original Assignee
Fundacion Publica Andaluza Para La Gestion de la Investigacion En Salud De Sevilla
Universidad Pablo de Olavide
Fundacion Publica Andaluza Progreso y Salud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Publica Andaluza Para La Gestion de la Investigacion En Salud De Sevilla, Universidad Pablo de Olavide, Fundacion Publica Andaluza Progreso y Salud filed Critical Fundacion Publica Andaluza Para La Gestion de la Investigacion En Salud De Sevilla
Priority to ES201330636A priority Critical patent/ES2523903B1/es
Priority to PCT/ES2014/070378 priority patent/WO2014177747A1/es
Priority to EP14791963.3A priority patent/EP2993475A4/en
Priority to US14/888,197 priority patent/US20190194749A1/en
Priority to CN201480038055.XA priority patent/CN106164673A/zh
Publication of ES2523903A1 publication Critical patent/ES2523903A1/es
Application granted granted Critical
Publication of ES2523903B1 publication Critical patent/ES2523903B1/es
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática.#La presente invención describe un método de diagnóstico de la fibrosis hepática, que comprende detectar el nivel de expresión del gen GATA-4, o la cantidad de la proteína GATA-4, en la muestra biológica aislada de tejido hepático, y kit de diagnóstico.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19

Claims (1)

  1. imagen1
    imagen2
    imagen3
ES201330636A 2013-04-30 2013-04-30 Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática Expired - Fee Related ES2523903B1 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201330636A ES2523903B1 (es) 2013-04-30 2013-04-30 Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática
PCT/ES2014/070378 WO2014177747A1 (es) 2013-04-30 2014-04-30 Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática
EP14791963.3A EP2993475A4 (en) 2013-04-30 2014-04-30 METHOD OF OBTAINING DATA IN THE DIFFERENTIAL DIAGNOSIS OF HEPATIC FIBROSIS
US14/888,197 US20190194749A1 (en) 2013-04-30 2014-04-30 Method for obtaining useful data for the differential diagnosis of liver fibrosis
CN201480038055.XA CN106164673A (zh) 2013-04-30 2014-04-30 用于获取对肝纤维化鉴别诊断有用的数据的方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330636A ES2523903B1 (es) 2013-04-30 2013-04-30 Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática

Publications (2)

Publication Number Publication Date
ES2523903A1 ES2523903A1 (es) 2014-12-02
ES2523903B1 true ES2523903B1 (es) 2015-09-09

Family

ID=51843200

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201330636A Expired - Fee Related ES2523903B1 (es) 2013-04-30 2013-04-30 Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática

Country Status (5)

Country Link
US (1) US20190194749A1 (es)
EP (1) EP2993475A4 (es)
CN (1) CN106164673A (es)
ES (1) ES2523903B1 (es)
WO (1) WO2014177747A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110850091B (zh) * 2019-11-13 2023-08-04 中国科学院生态环境研究中心 用于检测赭曲霉毒素a的荧光探针与成套试剂

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2000278128B2 (en) * 2000-08-21 2006-07-20 Assistance Publique - Hopitaux De Paris Diagnosis method of fibrotic disease using biochemical markers
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
FR2870348B1 (fr) * 2004-05-14 2010-08-27 Univ Angers Methode pour diagnostiquer la presence et/ou la severite d'une pathologie hepathique chez un sujet
US20140011211A1 (en) * 2004-05-14 2014-01-09 Centre Hospitalier Universitaire D'angers Method of diagnosing the presence and/or severity of a hepatic pathology in an individual and/or of monitoring the effectiveness of a treatment for one such pathology
EP1626280B1 (en) * 2004-08-12 2007-02-14 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
TW200745556A (en) * 2006-01-24 2007-12-16 Ind Tech Res Inst Biomarkers for liver fibrotic injury
CA2640644C (en) * 2006-01-31 2013-11-26 Asubio Pharma Co., Ltd. A method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
ES2325715B1 (es) * 2007-08-03 2010-06-17 Genetrix, S.L. Poblacion de celulas madre adultas derivadas de tejido adiposo cardiaco y su uso en regeneracion cardiaca.

Also Published As

Publication number Publication date
CN106164673A (zh) 2016-11-23
EP2993475A4 (en) 2016-12-21
ES2523903A1 (es) 2014-12-02
WO2014177747A1 (es) 2014-11-06
US20190194749A1 (en) 2019-06-27
EP2993475A1 (en) 2016-03-09

Similar Documents

Publication Publication Date Title
WO2015031694A3 (en) Oligonucleotide probes and uses thereof
ZA201705032B (en) Blood based biomarkers for diagnosing atherosclerotic coronary artery disease
WO2015157407A8 (en) Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
BR112017010414A2 (pt) métodos e composições para radiomarcação com 18f de substâncias biológicas
BR112014031365A2 (pt) métodos de detectar doenças ou condições
WO2016063068A3 (en) Method and apparatus for the analysis of compounds
EP4060048A3 (en) Non-invasive diagnostic method for diagnosing bladder cancer
WO2015071876A3 (en) Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers.
WO2016040784A3 (en) Systems and methods for estimating histological features from medical images using a trained model
EP3586129C0 (en) METHOD FOR ACCURATE DIAGNOSIS OF BIOMARKERS TARGETED AGAINST DISEASES IN LIQUID BIOPSY
EP3690063A3 (en) Diagnosis of lung cancer
BR112018009463A8 (pt) ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
ES2684758T3 (es) Procedimiento para diagnosticar fibrosis hepática
EP2937421A3 (en) Biomarker for predicting effect of an anti-C-met antibody
ES2544984T3 (es) Detección de la descomposición de enzimas en un elemento de ensayo por liberación controlada de un analito protegido
ES2437240B1 (es) Método de obtención de datos útiles para el diagnóstico, pronóstico y clasificación de los pacientes con enfermedad pulmonar obstructiva crónica (EPOC) y/o cáncer de pulmón
ES2523903B1 (es) Método de obtención de datos útiles para el diagnóstico diferencial de la fibrosis hepática
ES2641554T3 (es) Kit de piezas para colocación de anclaje quirúrgico
ES2493069T3 (es) CYBP como marcador del cáncer de pulmón
ES2566934T3 (es) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
WO2014169011A3 (en) Methods for treating immune diseases
EP3642366C0 (en) CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR DIAGNOSING ALZHEIMER’S DISEASE
BR112017027304A2 (pt) método para o diagnóstico de doença de farber
ES2482468B1 (es) Método de obtención de datos útiles para el diagnóstico diferencial del cáncer de pulmón
PL3449009T3 (pl) Biomarkery mikroRNA we krwi do diagnozowania choroby Alzheimera

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2523903

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150909

FD2A Announcement of lapse in spain

Effective date: 20210915